Loading…
Milestone Pharmaceuticals Inc. is projected to rise to $1.48 by 2027, a +16% move from its current price of $1.28. MIST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.24 | $1.28 | $1.32 | +0.08% |
| Jul 14 | $1.23 | $1.28 | $1.34 | +0.16% |
| Jul 15 | $1.22 | $1.28 | $1.35 | +0.23% |
| Jul 16 | $1.21 | $1.28 | $1.36 | +0.31% |
| Jul 17 | $1.20 | $1.28 | $1.37 | +0.39% |
| Jul 18 | $1.20 | $1.29 | $1.38 | +0.47% |
| Jul 19 | $1.19 | $1.29 | $1.39 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.19 | $1.29 | $1.39 | +0.55% |
| Week 2 | $1.16 | $1.29 | $1.45 | +1.10% |
| Week 3 | $1.14 | $1.30 | $1.49 | +1.65% |
| Week 4 | $1.12 | $1.31 | $1.53 | +2.21% |
| Week 5 | $1.10 | $1.32 | $1.57 | +2.77% |
| Week 6 | $1.09 | $1.32 | $1.60 | +3.33% |
| Week 7 | $1.08 | $1.33 | $1.64 | +3.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of cardiovascular medicines in the United States and Canada.
It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
The company is developing etripamil for AFib-RVR and has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize ettripamil. Milestone Pharmaceuticals Inc. was incorporated in 2003 and is headquartered in Montreal, Canada.
Milestone Pharmaceuticals Inc. (MIST) trades with a current price of $1.31 and a market capitalization of $163.09M, ranked 3965 by market cap.
The near-term price outlook is reflected in the provided forecasts, with 2026 averaging $1.31 and a max of $1.87, followed by gradual upside into the late 2020s and beyond.
Longer-term forecasts show meaningful upside, with the 2030 average $2.04 and a max of $3.03 (ROI 55.5%), and the 2050 average of $11.57 with a max of $22.24 (ROI 783.2%). These figures imply a bullish path for the stock over the multi-year horizon.
A major floor 21.1% below — a decisive break under it would weaken the trend.
The nearest floor, 5.5% below — buyers have tended to step in here.
The nearest ceiling, 12.5% above — a clean break opens room to run.
A major ceiling 71.9% above — clearing it would confirm fresh momentum.
Key MIST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MIST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.28 | Sell | $1.29 | Sell |
| MA 10 | $1.30 | Sell | $1.29 | Sell |
| MA 20 | $1.29 | Sell | $1.31 | Sell |
| MA 50 | $1.45 | Sell | $1.42 | Sell |
| MA 100 | $1.57 | Sell | $1.55 | Sell |
| MA 200 | $1.82 | Sell | $1.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.26 | Neutral |
| Stoch RSI (14) | 73.56 | Neutral |
| CCI (20) | -33.00 | Neutral |
| Williams %R (14) | -50.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -1.54 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 50.00 | Neutral |
| TRIX (15) | -0.51 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 40.93 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 1.26 | Buy |
| ADX (14) | 20.26 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is described as BULLISH overall. The RSI(14) sits at 50, with the 50-day simple moving average at $1.46 and the 200-day simple moving average at $1.83.
Key near-term support is $1.21 and resistance is $1.44, with a 30-day price range from $1.07 to $1.60. A move above resistance or below support could indicate the next directional bias in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.01 | $1.28 | $1.82 | 0% | Neutral | |
| $1.17 | $1.48 | $1.99 | +16% | Neutral | |
| $1.29 | $1.68 | $2.35 | +31% | Bullish | |
| $1.30 | $1.74 | $2.51 | +36% | Bullish | |
| $1.41 | $1.94 | $2.87 | +51% | Bullish | |
| $1.74 | $2.43 | $3.69 | +90% | Bullish | |
| $1.93 | $2.75 | $4.25 | +115% | Bullish | |
| $2.05 | $2.98 | $4.68 | +132% | Bullish | |
| $2.00 | $2.96 | $4.73 | +131% | Bullish | |
| $2.01 | $3.02 | $4.91 | +136% | Bullish | |
| $2.91 | $4.70 | $8.17 | +267% | Bullish | |
| $5.75 | $10.60 | $20.25 | +728% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.01 | $1.28 | $1.57 | +0.00% |
| August 2026 | $1.16 | $1.37 | $1.67 | +7.33% |
| September 2026 | $1.15 | $1.37 | $1.69 | +0.03% |
| October 2026 | $1.14 | $1.37 | $1.70 | -0.26% |
| November 2026 | $1.18 | $1.42 | $1.78 | +3.52% |
| December 2026 | $1.19 | $1.44 | $1.82 | +1.50% |
Click any year to see its month-by-month MIST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MIST could reach as high as $1.82, with a base case around $1.28 and support toward $1.01 — roughly 0% from $1.28. Price action looks broadly range-bound.
Expect MIST to range from $1.17 to $1.99 through 2027. The $1.48 average target implies a +16% move from current prices. That is up +16% on the projected 2026 average. A consolidation phase looks the most probable path here.
The MIST price prediction for 2028 points to an average of $1.68 (low $1.29, high $2.35) — a potential gain of +31% on today's $1.28. Momentum favours further upside here.
In 2029, MIST is projected to trade between $1.30 and $2.51, averaging $1.74 — a potential gain of +36% from today's $1.28. That is up +4% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Milestone Pharmaceuticals Inc.'s 2030 outlook centres on $1.94, within a $1.41 to $2.87 range. That is up +11% on the projected 2029 average. That marks a +51% change versus current levels. Momentum favours further upside here.
By 2031, MIST could reach as high as $3.69, with a base case around $2.43 and support toward $1.74 — roughly +90% from $1.28. Buyers look set to stay in control over this stretch.
Expect MIST to range from $1.93 to $4.25 through 2032. The $2.75 average target implies a +115% move from current prices. That is up +13% on the projected 2031 average. Momentum favours further upside here.
The MIST price prediction for 2033 points to an average of $2.98 (low $2.05, high $4.68) — a potential gain of +132% on today's $1.28. Buyers look set to stay in control over this stretch.
In 2034, MIST is projected to trade between $2.00 and $4.73, averaging $2.96 — a potential gain of +131% from today's $1.28. That is -1% versus the projected 2033 average. Momentum favours further upside here.
Milestone Pharmaceuticals Inc.'s 2035 outlook centres on $3.02, within a $2.01 to $4.91 range. That is up +2% on the projected 2034 average. That marks a +136% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, MIST could reach as high as $8.17, with a base case around $4.70 and support toward $2.91 — roughly +267% from $1.28. Momentum favours further upside here.
Expect MIST to range from $5.75 to $20.25 through 2050. The $10.60 average target implies a +728% move from current prices. That is up +125% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MIST today (≈ 781.25 MIST) could be worth
$8,282.04
+$7,282.04 (+728%) by 2050 · US Dollar
Based on the average projected MIST price of $10.6 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MISTwould be worth at today's price.
$1,000 invested in MIST on Jul 10, 2025 (≈ 390.625009 MIST) would be worth
$500
-$500 (-50.0%) today · 0.50× · US Dollar
Based on a MIST entry price of $2.56 vs. today's $1.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.32 | $969.7 | -3.0% |
| 1 month ago | $1.22 | $1,049.18 | +4.9% |
| 3 months ago | $2.02 | $633.66 | -36.6% |
| 6 months ago | $1.96 | $653.06 | -34.7% |
| 1 year ago | $2.56 | $500 | -50.0% |
| All time (5.0y) ago | $5.63 | $227.35 | -77.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MIST forecast.
Our base-case forecast reaches $2.60 around 2032.
Implied market cap at $2.60: $323.69M
The multi-year forecast shows accelerating upside, with the 2030 average price at $2.04 and an ROI of 55.5%, suggesting a substantial increase from current levels if realized. By 2040 the forecasted average rises to $5.09 with an ROI of 288.6%, underscoring a continued bullish trajectory.
By 2050, the forecast projects an average price of $11.57 and a max of $22.24, with an ROI of 783.2%. These figures reflect expected continued development in cardiovascular medicines and etripamil-related programs, alongside ongoing partnerships. While these estimates illustrate potential upside, they are not guarantees and carry inherent uncertainty.
Tap a question to reveal the answer.
2030 forecast: average price $2.04, with a min of $1.48 and a max of $3.03, and an ROI of 55.5%.
Forecasts show a bullish trajectory with rising averages from 2027 onward (e.g., 2027 average $1.52; 2028 average $1.75; 2029 average $1.81; 2030 average $2.04) and a 2050 average of $11.57 with a 783.2% ROI, but these are estimates and not guarantees.
Yes. The max forecast reaches $5.07 in 2034 and $5.26 in 2035, with higher upside projected later (e.g., 2040 max $8.89, 2050 max $22.24).
Sentiment: BULLISH. RSI(14) is 50, SMA50 is $1.46, SMA200 is $1.83. Support is $1.21 and resistance is $1.44, with a 30-day range of $1.07–$1.60.
Current price is $1.31 and market cap is $163.09M; the stock is ranked 3965 by market cap.
Milestone Pharmaceuticals Inc. Community Discussion
0Share your Milestone Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.